43,847 Shares in Progyny, Inc. $PGNY Bought by Summit Global Investments

Summit Global Investments bought a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, Holdings Channel.com reports. The fund bought 43,847 shares of the company’s stock, valued at approximately $1,105,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PGNY. Toth Financial Advisory Corp lifted its stake in Progyny by 21.3% during the third quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after purchasing an additional 480 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Progyny in the second quarter valued at $29,000. State of Wyoming grew its stake in shares of Progyny by 3.5% in the third quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after buying an additional 1,015 shares in the last quarter. Nykredit A S purchased a new stake in shares of Progyny in the 2nd quarter valued at $38,000. Finally, Allworth Financial LP raised its holdings in shares of Progyny by 71.7% in the 2nd quarter. Allworth Financial LP now owns 3,259 shares of the company’s stock valued at $94,000 after buying an additional 1,361 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity at Progyny

In related news, COO Melissa Cummings sold 1,879 shares of Progyny stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total value of $321,310.00. Following the transaction, the director directly owned 6,792 shares of the company’s stock, valued at $189,768.48. The trade was a 62.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 17,282 shares of company stock worth $475,790. Company insiders own 9.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Leerink Partners set a $38.00 target price on Progyny in a report on Wednesday, July 22nd. Barclays dropped their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 12th. BTIG Research boosted their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, August 21st. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.36.

Progyny Price Performance

Shares of PGNY stock opened at $29.19 on Monday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The stock has a market capitalization of $2.24 billion, a PE ratio of 31.73, a P/E/G ratio of 2.01 and a beta of 1.02. The firm has a 50 day moving average of $26.88 and a two-hundred day moving average of $24.43.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same quarter in the previous year, the firm posted $0.19 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Analysts expect that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.